A Race Against Time: The Fight to Treat Duchenne Muscular Dystrophy

A Race Against Time: The Fight to Treat Duchenne Muscular Dystrophy
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Aptamer-conjugated gold nanoparticles offer a precise method for targeting muscle stem cells in Duchenne Muscular Dystrophy (DMD), addressing a major challenge in gene therapy. By ensuring microRNA therapies reach regenerative muscle cells with high specificity, this approach enhances treatment efficacy while minimizing off-target effects. Recent findings, published in Nature Communications, confirm that the platform is non-toxic and does not trigger immune reactions, marking a crucial step toward clinical translation and potential therapeutic applications.

https://www.nature.com/articles/s41467-024-55223-9

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Biomedical Engineering and Bioengineering
Technology and Engineering > Biological and Physical Engineering > Biomedical Engineering and Bioengineering
Agriculture
Life Sciences > Biological Sciences > Agriculture

Related Collections

With Collections, you can get published faster and increase your visibility.

Women's Health

A selection of recent articles that highlight issues relevant to the treatment of neurological and psychiatric disorders in women.

Publishing Model: Hybrid

Deadline: Ongoing

Tumor Microenvironment Crosstalk and Therapeutic Implications

With this cross-journal Collection, the editors at Nature Immunology, Nature Communications, Communications Medicine and Scientific Reports invite manuscripts that highlight cutting-edge research on TME crosstalk and its therapeutic implications. Topics of interest include immune modulation and checkpoint pathways, cancer-associated fibroblasts and stromal remodeling, angiogenesis and vascular normalization, metabolic reprogramming within the TME, and the role of microbiota in tumor-immune dynamics. We also welcome studies on novel therapeutic approaches that exploit TME vulnerabilities to advance cancer treatment.

Publishing Model: Hybrid

Deadline: Nov 02, 2026